title: [Current status of medical therapy for obesity and the potential of novel anti-obesity drug development].
abstract: Obesity-related diseases including diabetes, dyslipidemia, and hypertension worsen quality of life of patients and waste medical expenses. To reduce the excess body weight, anti-obesity drugs that reduce appetite or lipid absorption from the intestine have been developed. Only Mazindol can be used in Japan at present, whereas Orlistat was launched and very recently Lorcaserin and Qsymia have been accepted in the US and/or European countries. In addition, a variety of drugs having various mechanisms have been investigated in clinical and basic stages. Some anti-obesity drugs were withdrawn from the market because of their severe adverse effects, however, the tremendous research to develop novel, safety anti-obesity drugs is ongoing.
authors: Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki.
authors: Masamitsu
authors: M
authors: Nakazato
mesh_terms: D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D009765:Obesity / Q000188:drug therapy*
chemical_list: D019440:Anti-Obesity Agents